Nivolumab plus ipilimumab for untreated unresectable or metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
Technology appraisal guidance
Reference number: TA1065
Published:
Evidence
Documents containing the evidence that was used to develop the recommendations.